語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
The Indian Pharmaceutical Industry =...
~
SpringerLink (Online service)
The Indian Pharmaceutical Industry = Impact of Changes in the IPR Regime /
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
The Indian Pharmaceutical Industry/ by Yaeko Mitsumori.
其他題名:
Impact of Changes in the IPR Regime /
作者:
Mitsumori, Yaeko.
面頁冊數:
VII, 120 p. 36 illus., 28 illus. in color.online resource. :
Contained By:
Springer Nature eBook
標題:
Health economics. -
電子資源:
https://doi.org/10.1007/978-981-10-6790-7
ISBN:
9789811067907
The Indian Pharmaceutical Industry = Impact of Changes in the IPR Regime /
Mitsumori, Yaeko.
The Indian Pharmaceutical Industry
Impact of Changes in the IPR Regime /[electronic resource] :by Yaeko Mitsumori. - 1st ed. 2018. - VII, 120 p. 36 illus., 28 illus. in color.online resource. - SpringerBriefs in Health Care Management and Economics,2193-1704. - SpringerBriefs in Health Care Management and Economics,.
Chapter 1: Introduction -- Chapter 2: Historical Background and Current Status of Indian Pharmaceutical Industry and Indian Patents Regime -- Chapter 3: Research Subject and Methodology -- Chapter 4: Analysis of Preceding Studies -- Chapter 5: Analysis of Indian Pharmaceutical Industry Indicators-Data Analysis -- Chapter 6: Analysis of Patents Act Enforcement After Introduction of Product Patents -- Chapter 7: Applicability of Section 3 (d) -- Chapter 8: Conclusions and Future Challenges.
This study analyzes the impact of the revision of the Indian Patent Act (2005) on the Indian pharmaceutical industry, which has been achieving healthy growth over the past 30 to 40 years or more. As of 2005, the Indian pharmaceutical industry was ranked as No. 4 in the world in terms of volume and 15th in terms of value. WTO/TRIPS required India to revise its patent law, however, and to introduce product patents in the pharmaceutical field. Many not only in India but also in the world had argued that the local pharmaceutical industry could deteriorate once a strong patent law (such as a product patent) was introduced. However, the Indian pharmaceutical industry has continued to develop rapidly even after the revision of the patent law in 2005. This present study started with efforts to work out the reason the Indian pharmaceutical industry successfully expanded even after the introduction of product patents. The study found that a unique article (the so-called '3-d‘) inserted in the Patent Act 2005 might have played a role in diminishing or preventing a negative impact from the introduction of a strong patent system, such as a product patents. The study also considers that a change of the business model adopted by the Indian pharmaceutical industry might have contributed to diminishing the effect of the negative impact from the introduction of a strong patent law. This study also covers recent developments in India regarding intellectual property rights and the pharmaceutical industry. One is India’s very first compulsory license granted to an Indian pharmaceutical company, Natco, against the large German pharmaceutical firm Bayer; and the second is the Supreme Court decision on Novartis’ Gleevec. The study analyzes the fundamental problems that caused these two events: access to medicine and gaps in the concept of intellectual property in the pharmaceutical industry. As possible solutions to these fundamental issues, this book explores the ideas of voluntary licensing and tiered pricing.
ISBN: 9789811067907
Standard No.: 10.1007/978-981-10-6790-7doiSubjects--Topical Terms:
810102
Health economics.
LC Class. No.: RA410-410.9
Dewey Class. No.: 338.473621
The Indian Pharmaceutical Industry = Impact of Changes in the IPR Regime /
LDR
:03927nam a22003975i 4500
001
995521
003
DE-He213
005
20200630010439.0
007
cr nn 008mamaa
008
201225s2018 si | s |||| 0|eng d
020
$a
9789811067907
$9
978-981-10-6790-7
024
7
$a
10.1007/978-981-10-6790-7
$2
doi
035
$a
978-981-10-6790-7
050
4
$a
RA410-410.9
072
7
$a
KCQ
$2
bicssc
072
7
$a
BUS069000
$2
bisacsh
072
7
$a
KCVJ
$2
thema
082
0 4
$a
338.473621
$2
23
100
1
$a
Mitsumori, Yaeko.
$4
aut
$4
http://id.loc.gov/vocabulary/relators/aut
$3
1206081
245
1 4
$a
The Indian Pharmaceutical Industry
$h
[electronic resource] :
$b
Impact of Changes in the IPR Regime /
$c
by Yaeko Mitsumori.
250
$a
1st ed. 2018.
264
1
$a
Singapore :
$b
Springer Singapore :
$b
Imprint: Springer,
$c
2018.
300
$a
VII, 120 p. 36 illus., 28 illus. in color.
$b
online resource.
336
$a
text
$b
txt
$2
rdacontent
337
$a
computer
$b
c
$2
rdamedia
338
$a
online resource
$b
cr
$2
rdacarrier
347
$a
text file
$b
PDF
$2
rda
490
1
$a
SpringerBriefs in Health Care Management and Economics,
$x
2193-1704
505
0
$a
Chapter 1: Introduction -- Chapter 2: Historical Background and Current Status of Indian Pharmaceutical Industry and Indian Patents Regime -- Chapter 3: Research Subject and Methodology -- Chapter 4: Analysis of Preceding Studies -- Chapter 5: Analysis of Indian Pharmaceutical Industry Indicators-Data Analysis -- Chapter 6: Analysis of Patents Act Enforcement After Introduction of Product Patents -- Chapter 7: Applicability of Section 3 (d) -- Chapter 8: Conclusions and Future Challenges.
520
$a
This study analyzes the impact of the revision of the Indian Patent Act (2005) on the Indian pharmaceutical industry, which has been achieving healthy growth over the past 30 to 40 years or more. As of 2005, the Indian pharmaceutical industry was ranked as No. 4 in the world in terms of volume and 15th in terms of value. WTO/TRIPS required India to revise its patent law, however, and to introduce product patents in the pharmaceutical field. Many not only in India but also in the world had argued that the local pharmaceutical industry could deteriorate once a strong patent law (such as a product patent) was introduced. However, the Indian pharmaceutical industry has continued to develop rapidly even after the revision of the patent law in 2005. This present study started with efforts to work out the reason the Indian pharmaceutical industry successfully expanded even after the introduction of product patents. The study found that a unique article (the so-called '3-d‘) inserted in the Patent Act 2005 might have played a role in diminishing or preventing a negative impact from the introduction of a strong patent system, such as a product patents. The study also considers that a change of the business model adopted by the Indian pharmaceutical industry might have contributed to diminishing the effect of the negative impact from the introduction of a strong patent law. This study also covers recent developments in India regarding intellectual property rights and the pharmaceutical industry. One is India’s very first compulsory license granted to an Indian pharmaceutical company, Natco, against the large German pharmaceutical firm Bayer; and the second is the Supreme Court decision on Novartis’ Gleevec. The study analyzes the fundamental problems that caused these two events: access to medicine and gaps in the concept of intellectual property in the pharmaceutical industry. As possible solutions to these fundamental issues, this book explores the ideas of voluntary licensing and tiered pricing.
650
0
$a
Health economics.
$2
bicssc
$3
810102
650
0
$a
Health care management.
$3
1148454
650
0
$a
Health services administration.
$3
564005
650
0
$a
Globalization.
$3
554884
650
0
$a
Markets.
$3
575391
650
1 4
$a
Health Economics.
$3
786205
650
2 4
$a
Health Care Management.
$3
1019864
650
2 4
$a
Emerging Markets/Globalization.
$3
881676
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer Nature eBook
776
0 8
$i
Printed edition:
$z
9789811067891
776
0 8
$i
Printed edition:
$z
9789811067914
830
0
$a
SpringerBriefs in Health Care Management and Economics,
$x
2193-1704
$3
1286511
856
4 0
$u
https://doi.org/10.1007/978-981-10-6790-7
912
$a
ZDB-2-ECF
912
$a
ZDB-2-SXEF
950
$a
Economics and Finance (SpringerNature-41170)
950
$a
Economics and Finance (R0) (SpringerNature-43720)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入